TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:14
Aprea Therapeutics Inc. ( APRE ) https://atrinpharma.com
3.37USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-9.89%
APRE
SPY
32.66%
-94.33%
APRE
SPY
108.59%
-99.66%
APRE
SPY
302.52%
APRE
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
18.12
-8.13
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.34
14.20
0.83
-84.71
0.00
0.54
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-729.56
99.06
-734.44
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.1104
-66.86
-67.19
1.03
Other Earnings and Cash Flow Stats:
Aprea Therapeutics Inc. ( APRE ) Net Income TTM ($MM) is -13.51
Aprea Therapeutics Inc. ( APRE ) Operating Income TTM ($MM) is -14.77
Aprea Therapeutics Inc. ( APRE ) Owners' Earnings Annual ($MM) is 0.00
Aprea Therapeutics Inc. ( APRE ) Current Price to Owners' Earnings ratio is 0.00
Aprea Therapeutics Inc. ( APRE ) EBITDA TTM ($MM) is -14.75
Aprea Therapeutics Inc. ( APRE ) EBITDA Margin is -734.44%
Capital Allocation:
Aprea Therapeutics Inc. ( APRE ) has paid 0.00 dividends per share and bought back -2.204579 million shares in the past 12 months
Aprea Therapeutics Inc. ( APRE ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Aprea Therapeutics Inc. ( APRE ) Interest-bearing Debt ($MM) as of last quarter is 0
Aprea Therapeutics Inc. ( APRE ) Annual Working Capital Investments ($MM) are -2
Aprea Therapeutics Inc. ( APRE ) Book Value ($MM) as of last quarter is 21
Aprea Therapeutics Inc. ( APRE ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Aprea Therapeutics Inc. ( APRE ) has 26 million in cash on hand as of last quarter
Aprea Therapeutics Inc. ( APRE ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Aprea Therapeutics Inc. ( APRE ) has 5 common shares outstanding as of last quarter
Aprea Therapeutics Inc. ( APRE ) has 0 million USD of preferred stock value
Academic Scores:
Aprea Therapeutics Inc. ( APRE ) Altman Z-Score is -15.13 as of last quarter
Aprea Therapeutics Inc. ( APRE ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Aprea Therapeutics Inc. ( APRE ) largest shareholder is owning shares at 0.00 ($MM) value
Gilad Oren(an insider) Bought 500 shares of Aprea Therapeutics Inc. ( APRE ) for the amount of $1957.50 on 2024-10-23
11.75% of Aprea Therapeutics Inc. ( APRE ) is held by insiders, and 43.85% is held by institutions
Aprea Therapeutics Inc. ( APRE ) went public on 2019-10-03
Other Aprea Therapeutics Inc. ( APRE ) financial metrics:
FCF:-13.83
Unlevered Free Cash Flow:0.00
EPS:-2.55
Operating Margin:-729.56
Gross Profit Margin:99.06
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-68.96
Beta:1.03
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Aprea Therapeutics Inc. ( APRE ) :
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that target a critical pathway and various central targets in DNA damage response and cancer progression. Its lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.